Research

Hormonal

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GoodSupportsHIGH confidence
Weight loss was greatest with GLP-1/GIP dual agonists... GLP-1/GIP RA WM trials, patients experienced an average weight loss of 16.1 kg with treatment compared with 3.1 kg with placebo.
Aishwarya Prasad et al. · British Journal of Clinical Pharmacology · 2026

Why this rating

Based on large FDA-reviewed datasets (36,312 efficacy subjects) and exposure-adjusted analysis, though limited by short trial durations and lack of long-term real-world data.

Source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

Aishwarya Prasad et al. · British Journal of Clinical Pharmacology · 2026

DOI 10.1002/bcp.70515

cohort · n=36312Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →